Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 214 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
2. Cita con resumen
Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]
3. Cita con resumen
N.L.. Why gene-therapy drugs are so expensive. The Economist 2016:1. [Ref.ID 100562]
5. Cita con resumen
Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, Saag KG, Beukelman T, Winthrop KL, Baddley JW, Curtis JR. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheum 2016;68:56-66. [Ref.ID 99975]
6.
Boehncke W-H, Schön MP. Psoriasis. Lancet 2015;386:983-4. [Ref.ID 99530]
8.Tiene citas relacionadas
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]
9.Tiene citas relacionadas
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]
10.Tiene citas relacionadas
Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]
11.Tiene citas relacionadas Cita con resumen
Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]
12.Tiene citas relacionadas
Smith AJ, Dieppe P, Vemon K, Porter M, Blom AW. Failure rates of stemmed metal-on-metal hip replacements. Lancet 2012;380:106-7. [Ref.ID 93452]
13.Tiene citas relacionadas
Verheyen CPM, Verhaar JAN. Failure rates of stemmed metal-on-metal hip replacements. Lancet 2012;380:106. [Ref.ID 93451]
14.Tiene citas relacionadas
Amstutz HC, Le Duff MJ. Failure rates of stemmed metal-on-metal hip replacements. Lancet 2012;380:105. [Ref.ID 93450]
15. Cita con resumen
Aaby P, Whittle H, Benn CS. Why vaccine programmes can no longer ignore non-specific effects. BMJ 2012;345:25-8. [Ref.ID 93395]
17.Tiene citas relacionadas Cita con resumen
Smith AJ, Dieppe P, Vemon K, Porter M, Blom AW, on behalf of the National Joint Registry of England and Wales. Failure rates of stemmed metal-on-metal hip replacements: analysis of data from the National Joint Registry of England and Wales. Lancet 2012;379:1199-204. [Ref.ID 92552]
18.Tiene citas relacionadas
Sedrakyan A. Metal-on-metal failures—in science, regulation, and policy. Lancet 2012;379:1174-6. [Ref.ID 92549]
19.Tiene citas relacionadas
Heneghan C, Langton D, Thompson M. Ongoing problems with metal-on-metal hip iimplants. BMJ 2012;344:23-4. [Ref.ID 92507]
20.Tiene citas relacionadas Cita con resumen
Cohen D. Hip implants: how safe is metal on metal?. BMJ 2012;344:18-22. [Ref.ID 92506]
Seleccionar todas
 
 1 a 20 de 214 siguiente >>